Long-term Outcomes of Cilta-cel in Relapsed/Refractory Multiple Myeloma

30 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
CARTITUDE-1 evaluated cilta-cel in heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients with historically poor outcomes. At 60.3 months follow-up, 33% remained progression-free ≥5 years post-infusion, showing significant biomarker correlations and durable responses. Median overall survival (OS) was 60.6 months, supporting cilta-cel's potential curative role in RRMM.

Key Points:
- Research Problem/Question: Assess long-term efficacy of cilta-cel in RRMM.
- Methodology: Single infusion in CARTITUDE-1, with correlative analyses.
- Key Findings: 33% remained progression-free ≥5 years; biomarker correlations identified predictors.
- Significance/Impact: Demonstrates potential curative effect in RRMM.

Conclusion:
The long-term follow-up of CARTITUDE-1 highlights cilta-cel's remarkable efficacy in achieving prolonged progression-free survival and significant OS benefits in heavily pretreated RRMM patients.

Authors:
Peter Voorhees, Tom Martin, Yi Lin, Adam Cohen, Noopur Raje, Myo Htut, Abhinav Deol, Mounzer Agha, Jesus Berdeja, Binod Dhakal, Andrzej Jakubowiak, Samir Parekh, Hui Li, Rocio Montes de Oca, Huabin Sun, Nikoletta Lendvai, Deepu Madduri, Mythili Koneru, Nitin Patel, Sundar Jagannath.

_______________
Improving Lives | Finding the Cure

Founded in 1990, the International Myeloma Foundation (IMF) is the first and largest organization focusing specifically on multiple myeloma. The IMF’s reach extends to more than 525,000 members in 140 countries worldwide. The IMF is dedicated to improving the quality of lives of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy.

Subscribe to our channel: https://www.youtube.com/c/IMFMyeloma

Visit our website at: https://www.myeloma.org

Find us online:
Facebook: @myeloma | https://facebook.com/myeloma
X/Twitter: @IMFMyeloma | https://twitter.com/IMFmyeloma
Instagram: @imfmyeloma | https://www.instagram.com/imfmyeloma
LinkedIn: https://www.linkedin.com/company/international-myeloma-foundation

Support the IMF | Donate Now! https://fundraise.myeloma.org/give/523296/#!/donation/checkout?c_src=youtube

Category
Nonprofits & Activism
License
Standard YouTube License

The International Myeloma Foundation is committed to accessibility for all. That’s why all English-language videos uploaded to our YouTube channel feature human-transcribed closed captioning. This ensures more accurate captions for viewers who are Deaf or hard of hearing and improves the quality of automatic translations into other languages for our global audience.
Categoria
Oncology
Commenta per primo questo video.

Prossimo